ClinicalTrials.gg
RecruitingNCT07453459Updated Jul 27, 2026

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

An interventional study of Qualitative Interview and Virtual Visit Standard Instructions in Cervical Cancer and HPV Infection, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to female participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
25 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine — 4 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Washington University School of Medicine.

Planned enrollment
Largest of 18
100 · median 26
Started
2026
with 1 other
No phase
10 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine, this one has the largest planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 19th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 25 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

This study is testing and implementing an equity-focused, community-based intervention that improves women's access to cervical cancer screening and adherence to follow up after an abnormal result. The study's objective is to assess and compare the feasibility of different methods of distributing at-home HPV testing kits for cervical cancer screening among individuals who are under-screened.

03

Conditions studied

  • Cervical Cancer
  • HPV Infection

Keywords

  • Cervical cancer screening
  • Self-collection
  • At-home HPV test
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are age 25 or older
  • Has an intact cervix
  • Self-reports that they have not been screened for cervical cancer within the last 3 years for 25-64, 5 years for 65 or older
  • Has a cellphone that can receive texts (including verification codes) and an email account
  • Has access to the internet to engage with the Teal Health mobile app and complete a Zoom interview
  • Can read, speak, write and understand English well enough to take a survey and complete an interview

Exclusion criteria

Exclusion Criteria:

  • Abnormal vaginal bleeding or discharge
  • A history of cancer of the reproductive system
  • A compromised immune system
  • Prior Diethylstilbestrol (DES) exposure
  • Currently pregnant or are within 6 weeks of giving birth
  • Treatment for a cervical precancer (e.g., loop electrosurgical excision procedure or conization) in the last 25 years.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Aim 1: Standard instructions

    Participants will complete a sociodemographic questionnaire and will receive the standard instructions. After approximately 8 weeks, participants will be asked to participate in the qualitative interview.

    Behavioral: Qualitative Interview · Behavioral: Virtual Visit Standard Instructions

  • Experimental
    Aim 1: Standard instructions + in-person guidance

    Participants will complete a sociodemographic questionnaire and will receive the standard instructions and in-person navigation for registering for a consult to receive the at-home testing kit. After approximately 8 weeks, participants will be asked to participate in the qualitative interview.

    Behavioral: Qualitative Interview · Behavioral: Virtual Visit Standard Instructions + In-Person Registration Navigation

Interventions

  • BehavioralQualitative Interview

    Participants will participate in a semi-structured qualitative interview conducted with a research coordinator and guided by the Capability, Opportunity, Motivation, Behavior model (COM-B).

  • BehavioralVirtual Visit Standard Instructions

    Participants will be given information about the self-collection kit along with a QR code they can use to register with Teal and request the telehealth appointment needed to receive their Teal At-Home cervical cancer screening kit.

  • BehavioralVirtual Visit Standard Instructions + In-Person Registration Navigation

    Participants will be given information about the self-collection kit along with a QR code they can use to register with Teal and request the telehealth appointment needed to receive their Teal At-Home cervical cancer screening kit. Participants will scan the QR code and complete the registration process onsite with a study coordinator, leaving the event with a scheduled date and time for their telehealth appointment.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who returned HPV samples

    Feasibility of the distribution methods between groups will be measured by the return rate of at home, self-collected HPV samples. Outcome will be reported via Pearson's chi-square test.

    Time frame: Up to eight weeks after enrollment

  2. Proportion of participants with completed referral visits

    Outcome will be reported via Pearson's chi-square test.

    Time frame: Up to eight weeks after enrollment

  3. Time to sample return

    Outcome will be analyzed by nominal regression model.

    Time frame: Up to eight weeks after enrollment

  4. Time to referral

    Outcome will be analyzed by nominal regression model.

    Time frame: Up to eight weeks after enrollment

  5. Thematic findings addressing opportunity

    Will be assessed during semi-structured interviews with participants and analyzed according to the Capability, Opportunity, Motivation, Behavior (COM-B) model. Questions during the semi-structure interview will follow a guide. Answers to the questions will be analyzed for thematic findings. The following questions on the guide asked to the returners of kits: * What was your reaction for when you were offered the Teal kit? * How did the support from event staff, the virtual care visit, or people in your life influence your decision about using the kit? The following questions on the guide asked to the non-returners of kits: * What, if any, were the barriers that prevented you from completing it? \*Probe: For example, finding the time to use the kit or understanding the instructions * Was there anything that changed between the time you enrolled in the study and receiving the kit that made you decide to not complete the kit?

    Time frame: Eight weeks after enrollment

  6. Thematic findings addressing capability

    Will be assessed during semi-structured interviews with participants \& analyzed according to the COM-B model. Questions during the semi-structure interview will follow a guide. Answers will be analyzed for thematic findings. The following will be asked to returners of kits: * How confident are you in the results you received? Do you trust them? Why/why not? * Did you feel like you received enough information when you got the kit to know what to do? * How did you feel about your ability to correctly use the self-sampling kit? * Were there any physical difficulties or health issues that made it challenging for you to use the kit? If so, can you describe them? * Do you have any recommendations for improving access to Teal kits for at-home cervical cancer screening? The following will be asked to non-returners of kits: * What suggestions/changes do you think would make it easier for you to use the kit in the future?

    Time frame: Eight weeks after enrollment

  7. Thematic findings addressing motivation

    Will be assessed during semi-structured interviews with participants \& analyzed according to COM-B model. Questions will follow a guide. Answers will be analyzed for thematic findings. The following will be asked to returners of kits: * Feelings about cervical cancer screening? * Previous pap smear/HPV test for cervical cancer screening? Describe the experience. * Any concerns/uncertainties you had about using the kit? * What made you decide to use the kit? * What did you like/not like about using the kit? * What things got in the way of using the kit or made it easier? * Would you recommend the kit to a friend? * Would you use the kit in the future? * Thoughts on the importance/urgency of completing the kit? * Explanation of your beliefs about the potential benefits/downsides of using the kit? The following will be asked to non-returners of kits: -Can you describe any situations/experiences/barriers that influenced your decision not to complete \& return the kit?

    Time frame: Eight weeks after enrollment

  8. Thematic findings addressing behavior

    Will be assessed during semi-structured interviews with participants and analyzed according to the COM-B model. Questions during the semi-structure interview follow a guide. Answers to the questions will be analyzed for thematic findings. The following questions on the guide asked to all participants: -Before receiving the kit, what were some of the reasons you were overdue for cervical cancer screening?

    Time frame: Eight weeks after enrollment

Secondary outcomes

  1. Proportion of participants with positive results who completed follow-up

    Outcome will be reported via Pearson's chi-square test.

    Time frame: Up to eight weeks after results available

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Michelle Silver, PhD, ScM · Contactmichelle.silver@wustl.edu · 314-454-7903
    • Ashley Housten, OTD, MSCI · Sub investigator
    • Lindsay Kuroki, MD, MSCI · Sub investigator
    • Meera Muthukrishnan, PhD, MPH · Sub investigator
    • Trena Depel, VP · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 18 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2026
First posted
Mar 6, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Nov 15, 2027
CompletionEst.
Jan 15, 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07453459
Collaborators
Teal Health, Inc.
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Apr 17, 2026
Primary completion
Nov 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Michelle Silver, PhD, ScM
Contact
michelle.silver@wustl.edu
314-454-7903
Michelle Silver, PhD, ScM
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion